Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human T-cell lymphotropic-I-associated leukemia/lymphoma.

R S Siegel1, R B Gartenhaus, T M Kuzel

  • 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Adult T-cell leukemia/lymphoma (ATL), a rare but aggressive cancer linked to Human T-cell lymphotropic virus-I (HTLV-I), presents treatment challenges. Novel therapies show promise for achieving long-lasting remissions in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

ESMO open·2024
Same author

Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

JCO precision oncology·2019
Same author

Hepatitis C virus upregulates B-cell receptor signaling: a novel mechanism for HCV-associated B-cell lymphoproliferative disorders.

Oncogene·2015
Same author

Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5' terminal oligopyrimidine tract.

Oncogene·2010
Same author

PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.

Oncogene·2010
Same author

Interleukins in the treatment of mycosis fungoides.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia·2008

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Adult T-cell leukemia/lymphoma (ATL) is a hematologic malignancy strongly associated with Human T-cell lymphotropic virus-I (HTLV-I) infection.
  • HTLV-I infection is geographically widespread, but ATL develops in a small fraction (2-4%) of infected individuals.
  • ATL is typically an aggressive disease with a poor prognosis, often with survival rates less than one year.

Purpose of the Study:

  • To review the oncogenic role of HTLV-I in ATL development.
  • To summarize current treatment strategies and outcomes for ATL.
  • To highlight emerging therapies for ATL.

Main Methods:

  • Literature review of studies on HTLV-I and ATL.
  • Analysis of treatment efficacy for conventional chemotherapy.

Related Experiment Videos

  • Evaluation of novel therapeutic approaches.

    • Main Results:

    • Conventional chemotherapy offers limited durable responses in ATL, with complete response rates between 20-45% and short-lived remissions.
    • Emerging treatments, including monoclonal antibodies targeting the interleukin-2 receptor and combination therapy with interferon alfa and zidovudine, demonstrate activity.
    • A subset of patients treated with novel therapies may achieve long-lasting remissions.

    Conclusions:

    • ATL remains a challenging malignancy with poor outcomes using standard treatments.
    • Novel therapeutic strategies offer improved prospects for durable remissions in ATL patients.
    • Further research into HTLV-I oncogenesis and advanced therapies is crucial for improving ATL patient survival.